FDA Issues New Class Warning, Requirements for Gadolinium Contrast Agents

Drug Industry Daily
A A
The FDA is mandating a new class warning and labeling changes for all gadolinium-based contrast agents — as well as requiring manufacturers to conduct additional human and animal safety studies.

To View This Article:

Login

Subscribe To Drug Industry Daily